Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated February 11, 2026, discloses the vesting of Deferred Annual Bonus Plan (DABP) awards granted in 2023 to Persons Discharging Managerial Responsibilities (PDMRs). The awards, which included nil-cost options over Ordinary Shares and restricted awards over American Depositary Shares (ADS), completed a three-year restricted period ending February 8, 2026, and vested on February 9, 2026. The filing details the subsequent sale of shares by executives to meet tax liabilities.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, or debt metrics. It provides specific transaction data related to executive compensation:
- Share Prices on Vesting Date (Feb 9, 2026): Ordinary Shares closed at £21.59; ADS closed at $59.01.
- Transaction Volume: A total of 269,832 Ordinary Shares and 12,522 ADS vested across nine executives.
- Tax Sales: Executives sold portions of their vested awards on the London Stock Exchange (XLON) and New York Stock Exchange (XNYS) to cover tax obligations.
Material Changes
The filing does not report material changes to the company's financial position or operations. It strictly documents routine equity compensation events consistent with the shareholder-approved 2022 Remuneration Policy. There are no comparative period financial metrics provided in this document.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on business outlook, or discussion of corporate risks and contingencies. The document is a statutory notification of insider transactions under Rule 13a-16/15d-16.
Investor Verification Checklist
- Verify the total number of shares issued to executives against the company's authorized share capital and treasury stock records.
- Confirm the tax withholding rates implied by the ratio of shares sold to shares vested for each executive.
- Review the 2022 Remuneration Policy to ensure the vesting conditions and deferral periods align with the disclosed three-year timeline.
- Check subsequent filings for any changes in executive ownership percentages resulting from these transactions.